Toxicity of a second autologous peripheral blood stem cell transplant in patients with relapsed or recurrent multiple myeloma

Julianna Aleathea Burzynski, Juan J. Toro, Rakhi Chhaganbhai Patel, Shuko Lee, Rebecca Elizabeth Greene, Jose Leonel Ochoa-Bayona, Chris Frei, Cesar O. Freytes

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Toxicity associated with a second autologous peripheral blood stem cell transplant (APBSCT) in patients who relapse following initial APBSCT for multiple myeloma (MM) has not been well described. We conducted a retrospective, case-series of 25 consecutive patients who received a second APBSCT for relapsed or progressive disease following prior APBSCT to describe associated toxicity. Grade 3 or 4 toxicities were observed in 92% of patients after each APBSCT. More patients developed an elevated serum creatinine (4%vs. 36%; p = 0.011) following the second APBSCT. Median time to neutrophil engraftment was 10 days following both transplants (p = 0.428). Platelet engraftment was delayed by 2 days after the second APBSCT (median 12 vs.14 days; p < 0.025). There were two deaths before day 100. In conclusion, patients who undergo a second APBSCT for relapsed MM experience more nephrotoxicity. Delayed platelet engraftment and an 8% treatment-related mortality were observed following the second APBSCT.

Original languageEnglish (US)
Pages (from-to)1442-1447
Number of pages6
JournalLeukemia and Lymphoma
Volume50
Issue number9
DOIs
StatePublished - 2009

Fingerprint

Multiple Myeloma
Transplants
Blood Platelets
Peripheral Blood Stem Cells
Creatinine
Neutrophils
Recurrence
Mortality
Serum

Keywords

  • autologous
  • hematopoietic stem cell transplantation salvage therapy
  • Multiple myeloma
  • toxicity

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research
  • Medicine(all)

Cite this

Burzynski, J. A., Toro, J. J., Patel, R. C., Lee, S., Greene, R. E., Ochoa-Bayona, J. L., ... Freytes, C. O. (2009). Toxicity of a second autologous peripheral blood stem cell transplant in patients with relapsed or recurrent multiple myeloma. Leukemia and Lymphoma, 50(9), 1442-1447. https://doi.org/10.1080/10428190903085936

Toxicity of a second autologous peripheral blood stem cell transplant in patients with relapsed or recurrent multiple myeloma. / Burzynski, Julianna Aleathea; Toro, Juan J.; Patel, Rakhi Chhaganbhai; Lee, Shuko; Greene, Rebecca Elizabeth; Ochoa-Bayona, Jose Leonel; Frei, Chris; Freytes, Cesar O.

In: Leukemia and Lymphoma, Vol. 50, No. 9, 2009, p. 1442-1447.

Research output: Contribution to journalArticle

Burzynski, JA, Toro, JJ, Patel, RC, Lee, S, Greene, RE, Ochoa-Bayona, JL, Frei, C & Freytes, CO 2009, 'Toxicity of a second autologous peripheral blood stem cell transplant in patients with relapsed or recurrent multiple myeloma', Leukemia and Lymphoma, vol. 50, no. 9, pp. 1442-1447. https://doi.org/10.1080/10428190903085936
Burzynski, Julianna Aleathea ; Toro, Juan J. ; Patel, Rakhi Chhaganbhai ; Lee, Shuko ; Greene, Rebecca Elizabeth ; Ochoa-Bayona, Jose Leonel ; Frei, Chris ; Freytes, Cesar O. / Toxicity of a second autologous peripheral blood stem cell transplant in patients with relapsed or recurrent multiple myeloma. In: Leukemia and Lymphoma. 2009 ; Vol. 50, No. 9. pp. 1442-1447.
@article{94577c0812414884a8c87aaf25e6211c,
title = "Toxicity of a second autologous peripheral blood stem cell transplant in patients with relapsed or recurrent multiple myeloma",
abstract = "Toxicity associated with a second autologous peripheral blood stem cell transplant (APBSCT) in patients who relapse following initial APBSCT for multiple myeloma (MM) has not been well described. We conducted a retrospective, case-series of 25 consecutive patients who received a second APBSCT for relapsed or progressive disease following prior APBSCT to describe associated toxicity. Grade 3 or 4 toxicities were observed in 92{\%} of patients after each APBSCT. More patients developed an elevated serum creatinine (4{\%}vs. 36{\%}; p = 0.011) following the second APBSCT. Median time to neutrophil engraftment was 10 days following both transplants (p = 0.428). Platelet engraftment was delayed by 2 days after the second APBSCT (median 12 vs.14 days; p < 0.025). There were two deaths before day 100. In conclusion, patients who undergo a second APBSCT for relapsed MM experience more nephrotoxicity. Delayed platelet engraftment and an 8{\%} treatment-related mortality were observed following the second APBSCT.",
keywords = "autologous, hematopoietic stem cell transplantation salvage therapy, Multiple myeloma, toxicity",
author = "Burzynski, {Julianna Aleathea} and Toro, {Juan J.} and Patel, {Rakhi Chhaganbhai} and Shuko Lee and Greene, {Rebecca Elizabeth} and Ochoa-Bayona, {Jose Leonel} and Chris Frei and Freytes, {Cesar O.}",
year = "2009",
doi = "10.1080/10428190903085936",
language = "English (US)",
volume = "50",
pages = "1442--1447",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "9",

}

TY - JOUR

T1 - Toxicity of a second autologous peripheral blood stem cell transplant in patients with relapsed or recurrent multiple myeloma

AU - Burzynski, Julianna Aleathea

AU - Toro, Juan J.

AU - Patel, Rakhi Chhaganbhai

AU - Lee, Shuko

AU - Greene, Rebecca Elizabeth

AU - Ochoa-Bayona, Jose Leonel

AU - Frei, Chris

AU - Freytes, Cesar O.

PY - 2009

Y1 - 2009

N2 - Toxicity associated with a second autologous peripheral blood stem cell transplant (APBSCT) in patients who relapse following initial APBSCT for multiple myeloma (MM) has not been well described. We conducted a retrospective, case-series of 25 consecutive patients who received a second APBSCT for relapsed or progressive disease following prior APBSCT to describe associated toxicity. Grade 3 or 4 toxicities were observed in 92% of patients after each APBSCT. More patients developed an elevated serum creatinine (4%vs. 36%; p = 0.011) following the second APBSCT. Median time to neutrophil engraftment was 10 days following both transplants (p = 0.428). Platelet engraftment was delayed by 2 days after the second APBSCT (median 12 vs.14 days; p < 0.025). There were two deaths before day 100. In conclusion, patients who undergo a second APBSCT for relapsed MM experience more nephrotoxicity. Delayed platelet engraftment and an 8% treatment-related mortality were observed following the second APBSCT.

AB - Toxicity associated with a second autologous peripheral blood stem cell transplant (APBSCT) in patients who relapse following initial APBSCT for multiple myeloma (MM) has not been well described. We conducted a retrospective, case-series of 25 consecutive patients who received a second APBSCT for relapsed or progressive disease following prior APBSCT to describe associated toxicity. Grade 3 or 4 toxicities were observed in 92% of patients after each APBSCT. More patients developed an elevated serum creatinine (4%vs. 36%; p = 0.011) following the second APBSCT. Median time to neutrophil engraftment was 10 days following both transplants (p = 0.428). Platelet engraftment was delayed by 2 days after the second APBSCT (median 12 vs.14 days; p < 0.025). There were two deaths before day 100. In conclusion, patients who undergo a second APBSCT for relapsed MM experience more nephrotoxicity. Delayed platelet engraftment and an 8% treatment-related mortality were observed following the second APBSCT.

KW - autologous

KW - hematopoietic stem cell transplantation salvage therapy

KW - Multiple myeloma

KW - toxicity

UR - http://www.scopus.com/inward/record.url?scp=79952277849&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952277849&partnerID=8YFLogxK

U2 - 10.1080/10428190903085936

DO - 10.1080/10428190903085936

M3 - Article

C2 - 19637091

AN - SCOPUS:79952277849

VL - 50

SP - 1442

EP - 1447

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 9

ER -